Kesava Manikanta Achuta

Dr. Kesava Manikanta Achuta

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 June 2023 in Journal of Evaluation in Clinical Practice
Verified
Journal Article
Closed access
ASAditya Samitinjay
Aditya Samitinjay
KVKarnati Vaishnavi
Karnati Vaishnavi
RGReethika Gongireddy
Reethika Gongireddy
SKSai Charan Kulakarni
Sai Charan Kulakarni
RPRaveen Panuganti
Raveen Panuganti
RBRakesh Biswas
Rakesh Biswas

27 June 2025 in Pharmacoepidemiology
Verified
Journal Article
Open access
PDF file
JUJahnavi Udaikumar
Jahnavi Udaikumar
RNRithish Nimmagadda
Rithish Nimmagadda
VLVindhya vasini Lella
Vindhya vasini Lella
KAKesava Manikanta Achuta
Kesava Manikanta Achuta
SKSatwik Kuppili
Satwik Kuppili
RSRaiya Sarwar
Raiya Sarwar
Introduction: Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly encompassed under nonalcoholic fatty liver disease (NAFLD), is a growing global health burden associated with progression to cirrhosis and hepatocellular carcinoma. Resmetirom, a thyroid hormone receptor-β (THR-β) agonist, and semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1 RA), have emerged as promising agents targeting distinct metabolic and inflammatory pathways. This systematic review compares the safety and efficacy of resmetirom and semaglutide in MASLD. Methods: We conducted a comprehensive search of PubMed, Embase, and Google Scholar for randomized controlled trials and clinical studies published between January 2014 and April 2025, following PRISMA guidelines. Studies assessing the efficacy and safety of resmetirom and/or semaglutide in MASLD or NASH were included. Data extraction was performed by two independent reviewers, and a narrative synthesis was undertaken due to the heterogeneity in study design and outcome measures. Results: Fourteen studies encompassing over 4500 patients were analyzed. Resmetirom demonstrated consistent reductions in hepatic fat (≥30% in >50% of patients) and improvements in fibrosis (≥1 stage in up to 26.4% of patients), as evidenced in the MAESTRO-NASH trial. Semaglutide achieved higher rates of NASH resolution (up to 62.9%) without worsening fibrosis, especially among patients with type 2 diabetes or obesity, although fibrosis improvement was less consistently observed. Resmetirom was well tolerated with low discontinuation rates, while semaglutide was associated with more frequent, yet manageable, gastrointestinal adverse events. Conclusions: Both resmetirom and semaglutide show therapeutic potential for MASLD. Resmetirom offers more consistent antifibrotic effects, while semaglutide excels in NASH resolution and metabolic improvement. The absence of direct comparative trials underscores the need for future head-to-head studies to guide tailored treatment strategies in MASLD management.